Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Peripheral Blood Flow Cytometry Classifies Pediatric Acute Leukemia

By LabMedica International staff writers
Posted on 25 Feb 2019
Historically, flow cytometry performed on the bone marrow aspirate (BMFC) has been the standard for the immunophenotypic characterization of acute leukemia. More...
Recent data have demonstrated the high sensitivity and specificity of peripheral blood flow cytometry for the diagnosis of pediatric leukemia.

Peripheral blood flow cytometry (PBFC) represents a less invasive approach to the immunophenotyping of the leukemic clone, which can also facilitate a quicker diagnosis and the opportunity to subsequently perform concurrent central venous access device placement, lumbar puncture with intrathecal chemotherapy administration, and bone marrow biopsy, if necessary, under a single anesthetic.

Medical laboratory scientists at St. Jude Children's Research Hospital (Memphis, TN, USA) collected peripheral blood and BM samples were collected in preservative‐free heparin or EDTA. Cells were washed twice in phosphate‐buffered saline and labeled with various combinations of monoclonal antibodies conjugated to fluorochromes directed against surface antigens or isotype‐matched nonreactive monoclonal antibodies. The samples were processed and analyzed using four or eight color stained cell preparations with FACSCalibur or FACSCanto II flow cytometers with FACSDiva software. A minimum of 20,000 cells per tube were counted. A diagnostic minimal residual disease (MRD) panel was also implemented.

The team identified 290 PBFC samples with concurrent BM evaluation. Based on the final immunophenotypic classification, the cases were distributed as follows: 108 B‐lymphoblastic leukemia (B‐ALL), 57 T‐lymphoblastic leukemia (T‐ALL), 116 acute myeloid leukemia (AML), and nine mixed‐phenotype acute leukemia (MPAL). Among all cases, five had a diagnostically significant discrepancy between PBFC and BM evaluation. In three cases, the immunophenotype by PBFC was consistent with early T‐cell precursor ALL (ETP‐ALL), whereas BM evaluation demonstrated MPAL. Two cases were suspicious for acute megakaryoblastic leukemia (AMKL) and MPAL, T/myeloid by PBFC, but were diagnosed as B‐ALL and T‐ALL in the BM.

The authors concluded that immunophenotypic classification by PBFC is accurate in more than 98% of all cases of pediatric leukemia with the rare exceptions of suspected ETP‐ALL, MPAL, and AMKL. These PBFC diagnoses should be confirmed with BM immunophenotyping. The study was published in the January 2019 issue of the journal Pediatric Blood & Cancer.

Related Links:
St. Jude Children's Research Hospital


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.